MedPage Today on MSN1d
Young Patient Dies After Receiving New Gene Therapy for Duchenne Muscular Dystrophy
A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
More than 800 people have been treated with Elevidys, the only approved treatment for Duchenne muscular dystrophy, the company said.
Becker's Hospital Review9h
1st patient death linked to muscular dystrophy treatment
Cambridge, Mass.-based Sarepta Therapeutics reported the first known death from its Duchenne muscular dystrophy gene therapy ...
MPR7h
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.
GEN - Genetic Engineering and Biotechnology News1d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
Gene-Therapy Maker Sarepta Tanks After Patient Death
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
BioPharma Dive1d
Duchenne patient dies after receiving Sarepta gene therapy
A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...
Father’s love, doctor’s courage: How a risky transplant saved a teen’s life
Dr. Arvinder Singh Soin faced an ethical challenge when a 17-year-old girl arrived in a coma with acute liver failure.
The Pharma Letter11h
Alarm over Elevidys patient death
Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) ...
Medical Xpress on MSN12d
Ammonia buildup kills liver cells but can be prevented using existing drug
YAQ-005, which has been patented by UCL Business (UCLB), the commercialization company for UCL, and licensed to UCL spinout ...
Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne ...
Sarepta Therapeutics Stock Sinks After Company Says Patient Taking Its Drug Dies
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.